Drugs / OC-EIEs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03393962 | Dec 2025 → Jan 2028 expected | ovarian cancer | Shenzhen Geno-Immune Medical Institute | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OC-EIEs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03393962 ↗ |
| Modality | Cell therapy | “Autologous ovarian cancer antigen-specific cytotoxic lymphocytes” NCT03393962 ↗ |
| Route | Intravenous | “injection via IV” NCT03393962 ↗ |